What is KPRX's P/E ratio?

Kiora Pharmaceuticals Inc (KPRX) currently trades at a P/E ratio of 408.37.

Kiora Pharmaceuticals Inc reports a Return on Equity (ROE) of -79.37%.

What is KPRX's dividend yield?

Kiora Pharmaceuticals Inc offers a dividend yield of 0.00%.

What is KPRX's Quality Score?

Our AI rates KPRX's overall financial quality at 8 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy KPRX?

Our AI Timing Score for KPRX is 4 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does KPRX belong to?

Kiora Pharmaceuticals Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Kiora Pharmaceuticals Inc (KPRX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

KPRX AI Analysis Summary

Our AI summary for KPRX: Kiora Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 408.37, ROE of -79.37%, a dividend yield of 0.00%. Its financial Quality Score stands at 8/100 — fundamentals below the market average. The AI Timing Score is 4/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

KPRX

Kiora Pharmaceuticals Inc

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 2.54

0.07 (2.83%) Day Change

Watchlist Portfolio Compare Chart

408.37

P/E

0.01

D/E

-79.4%

ROE

-52.1%

ROA

0.00%

Div Yield

-2.55

PEG

KIORA PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.54 Price 0.07 (2.83%) Day Change	NEWS SCORE: N/A

KPRX, the overall quality is not good ( Quality = 8) and the timing to buy is ...(Sign In to See)...

Loading chart...

8 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.54
PBV / Sector	0.79 / 44,105.10 GREAT
Earning Per Share	-2.57

PE / Sector	408.37 / 19.37
PEG or PE/Growth / Sector	-2.55 / 1.06
Average 1M Daily Value	0.06 M GREAT
Average 1W Daily Value	0.04 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 97.23
NPM Average (%) / Sector	22.47 / -1,697.84 GREAT
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-52.10 / 185,260.64
ROA Average (%) / Sector	-50.18 / 36,684.64
ROA Change Average (%) / Sector	-155.53 / 422,221.42
ROE (%) / Sector	-79.37 / 243,761.81
ROE Average (%) / Sector	-91.30 / 48,758.38
ROE Change Average (%) / Sector	-149.53 / 424,967.86
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 08:00:15
Symbol	KPRX
Name	KIORA PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	4.43 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	10.95 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 332 Encinitas Boulevard, Encinitas, CA, United States, 92024

Phone: 858 224 9600

Website: https://www.kiorapharma.com

Sector: Healthcare >> Biotechnology

Description: Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.